A PHASE IA DOSE-ESCALATION STUDY OF THE ANTI-FACTOR D MONOCLONAL ANTIBODY FRAGMENT FCFD4514S IN PATIENTS WITH GEOGRAPHIC ATROPHY

Abstract

Single-dose intravitreal FCFD4514S administrations were safe and well tolerated and not associated with any study drug-related ocular or systemic adverse events. These data support a multidose safety and tolerability assessment of FCFD4514S in geographic atrophy.